Craft

Faron

Stock Price

£1.8

2024-10-29

Market Capitalization

£188.4 M

2024-10-29

Faron Summary

Company Summary

Overview
Faron Pharmaceuticals is a biopharmaceutical company developing treatments for medical conditions with unmet needs. It offers Clevegen, an anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease, and vaccine development.
Type
Public
Status
Active
Founded
2007
HQ
Turku, FI | view all locations
Website
https://www.faron.com
Cybersecurity rating
Sectors

Key People

  • Markku Jalkanen

    Markku Jalkanen, Non-Executive Director

    • Juho Jalkanen

      Juho Jalkanen, Chief Executive Officer & Founder

    • Yrjö Wichmann

      Yrjö Wichmann, Interim Chief Financial Officer

    • Birge Berns

      Birge Berns, Interim Chief Medical Officer

    LocationsView all

    1 location detected

    • Turku HQ

      Finland

      Joukahaisenkatu 6

    Faron Financials

    Summary Financials

    Gross profit (FY, 2025)
    €1.3M
    Net income (FY, 2025)
    (€27.3M)
    Cash (FY, 2025)
    €12.3M
    EBIT (FY, 2025)
    (€19.0M)
    Enterprise value
    $200.7M

    Footer menu